Log In
Print
BCIQ
Print
Print this Print this
 

AllerT

  Manage Alerts
Collapse Summary General Information
Company Anergis S.A.
DescriptionBirch pollen allergy vaccine containing contiguous overlapping peptides (COP) derived from birch pollen
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsDesensitization for moderate to severe allergies to birch pollen
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today